ProForma 2.0
validated simple linear
KFLCSIPGMYYFAYHLTV
Back to Primary literature
Primary-literature peptidehigh evidence PepDiana evidence grade for a literature-derived identity; Medium indicates retained review flags, while High has no unresolved review flag.
PEPDIA-PLP-001454
gADP3
Aliases: gADP3
Normalized sequence
KFLCSIPGMYYFAYHLTV
18 amino acids
Release PepDiana-V1-20260620
33
Activity records
1
Source papers
32
Positive
1
Negative / threshold
Versioned scientific descriptors
Physicochemical properties and standard representations
Reported properties
No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.
Computed properties
physchem-20260620Molecular weight
2153.5624 Da
Molecular formula
C105H149N21O24S2
Theoretical pI
8.1638
Net charge at pH 7
0.8334
GRAVY
0.7556
Instability index
34.7111
Aromaticity
0.2778
Topological polar surface area
705.08 Ų
cLogP
-0.9272
Hydrogen-bond donors
26
Hydrogen-bond acceptors
28
Rotatable bonds
63
Method: PepDiana sequence/structure descriptor pipeline
Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6
Calculated: 2026-06-20T11:01:38.358971+00:00
Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200
Sequence representations
HELM 2.0
validated simple linear
PEPTIDE1{K.F.L.C.S.I.P.G.M.Y.Y.F.A.Y.H.L.T.V}$$$$V2.0
Canonical SMILES
validated
CCC(C)C(NC(=O)C(CO)NC(=O)C(CS)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccccc1)NC(=O)C(N)CCCCN)C(=O)N1CCCC1C(=O)NCC(=O)NC(CCSC)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccccc1)C(=O)NC(C)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(C(=O)O)C(C)C)C(C)O
Isomeric SMILES
validated
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O
Paper-level observations
Experimental evidence grouped by activity
Immunomodulatory 28 records
PMC12857376
28 observationsImmunomodulatoryAnti-inflammatoryPositive observation
Record detail gADP3 and AdipoRon interventions led to a significant reduction in IL-6 mRNA expression in comparison with the LPS group (p < 0.01) (Fig. 4A).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail gADP3 and AdipoRon interventions led to a substantial reduction in TNF-α expression (p < 0.01) (Fig. 4B).
- Measure
- qualitative
- Value
- substantial reduction
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail gADP3 intervention increased IL-10 mRNA levels in the thymus (p < 0.05) (Fig. 4C).
- Measure
- qualitative
- Value
- increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail both gADP3 and AdipoRon interventions led to a significant reduction in the levels of IL-6 and TNF-α in spleen tissue (p < 0.01) (Fig. 4D,E).
- Measure
- qualitative
- Value
- significant reduction
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail gADP3 intervention significantly increased IL-10 levels (p < 0.01) (Fig. 4F).
- Measure
- qualitative
- Value
- significantly increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the thymus were significantly reduced (p < 0.05) (Fig. 8A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the thymus were significantly reduced (p < 0.05) (Fig. 8A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the thymus were significantly reduced (p < 0.05) (Fig. 8A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 and AdipoRon interventions significantly reduced NF-κB p65 and MyD88 protein expression levels (p < 0.05) (Fig. 8D,E,F,G).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 and AdipoRon interventions significantly reduced NF-κB p65 and MyD88 protein expression levels (p < 0.05) (Fig. 8D,E,F,G).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 and AdipoRon intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the spleen were significantly reduced (p < 0.05) (Fig. 9A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 and AdipoRon intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the spleen were significantly reduced (p < 0.05) (Fig. 9A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail following gADP3 and AdipoRon intervention, mRNA expression levels of NF-κB p65, MyD88, and TLR4 in the spleen were significantly reduced (p < 0.05) (Fig. 9A,B,C).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 and AdipoRon interventions significantly reduced the expression levels of these two proteins (p < 0.05) (Fig. 9D,E,F,G).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 and AdipoRon interventions significantly reduced the expression levels of these two proteins (p < 0.05) (Fig. 9D,E,F,G).
- Measure
- qualitative
- Value
- significantly reduced
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail Subsequent to the administration of gADP3 and AdipoRon, a marked increase in AdipoR1 mRNA expression levels was observed in the thymus (p < 0.05) (Fig. 6A).
- Measure
- qualitative
- Value
- significantly increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 intervention resulted in a significant increase in AdipoR2 mRNA expression levels in the thymus (p < 0.05) (Fig. 6B).
- Measure
- qualitative
- Value
- significant increase
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail the intervention with gADP3 also elevated AdipoR2 mRNA expression in the spleen (p < 0.01) (Fig. 6G).
- Measure
- qualitative
- Value
- elevated
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 intervention significantly increased AMPK mRNA levels (p < 0.05) (Fig. 7A).
- Measure
- qualitative
- Value
- significantly increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 intervention significantly increased AMPK mRNA and protein levels in the spleen (p < 0.01) (Fig. 7D).
- Measure
- qualitative
- Value
- significantly increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail after interventions with AdipoRon and gADP3, both IgA and IgG levels were significantly elevated (p < 0.05) (Fig. 1C,D).
- Measure
- qualitative
- Value
- significantly elevated
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 intervention significantly elevated T4 and TSH levels (p < 0.05) (Fig. 1E,F).
- Measure
- qualitative
- Value
- significantly elevated
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail after the injection of AdipoRon and gADP3, both increased the levels of ALB and TP in the blood (p < 0.01) (Fig. 1A,B).
- Measure
- qualitative
- Value
- increased
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail Western blot analysis of thymus tissue revealed no significant changes in protein levels of either AdipoR1 or AdipoR2 (p > 0.05) (Fig. 6C,D,E).
- Measure
- qualitative
- Value
- no significant changes
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail Western blot analysis of thymus tissue revealed no significant changes in protein levels of either AdipoR1 or AdipoR2 (p > 0.05) (Fig. 6C,D,E).
- Measure
- qualitative
- Value
- no significant changes
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail gADP3 intervention significantly increased AMPK mRNA levels (p < 0.05) and also elevated AMPK expression levels, although without significant difference (p > 0.05) (Fig. 7A,B,C).
- Measure
- qualitative
- Value
- elevated... although without significant difference
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail changes in TLR4 protein levels in the thymus were not significant (p > 0.05) (Fig. 8D,E,F,G).
- Measure
- qualitative
- Value
- not significant
- Target
- goose
- Assay
- Not reported by source
ImmunomodulatoryPositive observation
Record detail changes in TLR4 protein levels in spleen tissue were not significant (p > 0.05) (Fig. 9D,E,F,G).
- Measure
- qualitative
- Value
- not significant
- Target
- goose
- Assay
- Not reported by source
Antioxidant 4 records
PMC12857376
4 observationsAntioxidantPositive observation
Record detail gADP3 and AdipoRon interventions led to a significant reduction in MDA content (p < 0.05) (Fig. 5A).
- Measure
- qualitative
- Value
- significant reduction
- Target
- goose
- Assay
- Not reported by source
AntioxidantPositive observation
Record detail gADP3 and AdipoRon interventions led to a substantial enhancement in GSH-Px activity (p < 0.05) (Fig. 5B).
- Measure
- qualitative
- Value
- substantial enhancement
- Target
- goose
- Assay
- Not reported by source
AntioxidantPositive observation
Record detail intervention with gADP3 and AdipoRon led to a substantial reduction in MDA levels (p < 0.01) (Fig. 5D).
- Measure
- qualitative
- Value
- substantial reduction
- Target
- goose
- Assay
- Not reported by source
AntioxidantPositive observation
Record detail intervention with gADP3 and AdipoRon did not mitigate the decrease in GSH-Px activity in spleen tissue induced by LPS (Fig. 5E).
- Measure
- qualitative
- Value
- did not mitigate
- Target
- goose
- Assay
- Not reported by source
Toxicity 1 records
PMC12857376
1 observationsToxicityGeneral ToxicNegative / threshold
Record detail gADP3 intervention... showed no statistically significant effect on COR (p > 0.05) (Fig. 1G).
- Measure
- qualitative
- Value
- no statistically significant effect
- Target
- goose
- Assay
- Not reported by source
Citation and release provenance
Cite this identity as PepDiana record PEPDIA-PLP-001454, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.
Record updated: 2026-06-22T07:14:26.229247+00:00